Metabolon Continues Investments in Scientific Innovation with Appointment of Rangaprasad (Ranga) Sarangarajan, Ph.D., in New Leadership Role as Chief Scientific Officer

Dr. Sarangarajan supports Metabolon’s mission to deliver metabolomics data and insights that expand and accelerate the impact of life sciences research in all its applications by leading the team to identify R&D applications across biopharma and diagnostics.

MORRISVILLE, N.C. – October 14, 2021 – Metabolon, Inc., the global leader in metabolomics solutions advancing drug development and precision medicine, has appointed Rangaprasad (Ranga) Sarangarajan, Ph.D., to the newly created role of Chief Scientific Officer (CSO).

“We are thrilled to have Ranga join Metabolon,” says Rohan Hastie, Ph.D., President and CEO, Metabolon. “He brings a unique blend of both deep technical expertise and business leadership experience, including more than a decade of leveraging the power of multi-omics technologies to build a successful commercial diagnostic and drug development portfolio.”

Metabolon’s industry-leading metabolomics solutions support the full drug development continuum, from biomarker discovery and understanding mechanism of action, through patient stratification, clinical trial safety, and efficacy management. As part of the Metabolon Leadership Team, Ranga will play a pivotal role in shaping the R&D strategy to drive innovation across Metabolon’s drug discovery and new product development roadmap.

In his previous role of Chief Scientific Officer & SVP Clinical and Translational Sciences at BERG, Ranga spent more than a decade leading multi-functional teams integrating biology, technology, and artificial intelligence analytics in the development of a multi-omic, biology-based platform for the discovery of disease-specific targets, therapeutic discovery, and diagnostics development. He established a robust pipeline of assets in various diseases and indications, leading several programs through early IND, enabling First-In-Human Phase 1 and proof-concept Phase 2 clinical program.

“Metabolomics has gained steady interest among researchers for its ability to get closer to the phenotype, and I am fortunate to join Metabolon, the recognized leading commercial metabolomics services provider,” says Ranga. “I am looking forward to helping Metabolon drive greater adoption of metabolomics as a powerful tool to advance drug development and life sciences research.”

Ranga has a Ph.D., in Pharmaceutical Sciences from the University of Cincinnati and a B.S., in Pharmacy from Maharaja Sayajirao University. He has extensively published in national/international peer-reviewed journals and is part of more than 40 pending or approved patents.